Evidence map›Paper›PMID 33733397›Full record

ArticleIrish journal of medical science2022

Familial pancreatic cancer: who should be considered for genetic testing?

Kinyas Kartal, Zoe Guan, Rong Tang, Molly Griffin, Yan Wang, Danielle Braun, Alison P Klein, Kevin S Hughes

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kinyas KartalDivision of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA. kkartal@kuh.ku.edu.tr.ORCID http://orcid.org/0000-0002-3338-363X
Zoe GuanDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Rong TangDivision of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Molly GriffinDivision of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Yan WangDivision of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Danielle BraunDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Alison P KleinDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institution, Baltimore, MD, USA.
Kevin S HughesDivision of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetermining how many female patients who underwent breast imaging meet the eligibility criteria for genetic testing for familial pancreatic cancer (FPC).

methodsA total of 42,904 patients seen at the Newton-Wellesley Hospital between 2007 and 2009 were retrospectively reviewed. The first four categories were based on pancreatic cancer-associated syndromes: (1) hereditary breast and ovarian cancer (HBOC), (2) Lynch syndrome (LS), (3) familial atypical multiple mole melanoma (FAMMM), and (4) family history of FPC (FH-FPC). PancPRO (5) and MelaPRO (6) categories were based on risk scores from Mendelian risk prediction tool.

resultsExactly 4445 of 42,904 patients were found to be in at least one of the six risk categories. About 5.7% of patients were classified as being at high risk for HBOC, 2.3% as being at high risk for LS, 0.1% as being at high risk for FAMMM, 0.1% as being at high risk for FH-FPC, 2.7% as being at high risk based on PancPRO, and 0.2% as being at high risk based on MelaPRO.

conclusionAbout 10.4% of the female patients were classified as being at high risk for FPC. This finding emphasizes the importance of applying criteria to the general population, in order to ensure that individuals with high risk are identified early.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisPancreatic NeoplasmsFemaleGenetic Predisposition to DiseaseGenetic TestingHumansRetrospective StudiesGenetic testingHigh risk individualsPancreatic cancerPancreatic cancer-associated syndromesRisk prediction

Identifiers

PMID33733397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.